Here’s a practical comparison of Vyvanse and Qelbree.
- What they are
- Vyvanse (lisdexamfetamine dimesylate): a stimulant ADHD medication. It’s a prodrug of dextroamphetamine.
- Qelbree (viloxazine extended-release): a non-stimulant ADHD medication with a norepinephrine reuptake–inhibiting action (with other serotonergic effects noted in older research).
- Primary indications and age
- Vyvanse: approved for ADHD in children and adults; also approved for binge eating disorder in adults.
- Qelbree: approved for ADHD in children aged 6–17 (as of current labeling); not approved for adults (check the latest labeling if you’re considering adults).
- How quickly they work
- Vyvanse: rapid onset typical of stimulants (often within hours); symptom control tends to be noticeable soon after starting or adjusting dose.
- Qelbree: non-stimulant with a slower, gradual onset; benefits may take several days to weeks to become clear.
- Mechanism and what it targets
- Vyvanse: increases dopamine and norepinephrine in the brain (stimulant effect) for improved attention and impulse control.
- Qelbree: lowers norepinephrine reuptake (non-stimulant); can help with ADHD symptoms without the stimulant-like surge in dopamine.
- Abuse potential and scheduling
- Vyvanse: Schedule II controlled substance (risk of misuse, dependence, withdrawal).
- Qelbree: not a stimulant and has a much lower potential for abuse.
- Common side effects and safety concerns
- Vyvanse: decreased appetite/weight loss, insomnia, increased heart rate/blood pressure, anxiety, dry mouth; can worsen tics or anxiety in some people; possible mood changes or, rarely, psychosis or mania in susceptible individuals.
- Qelbree: somnolence/fatigue, decreased appetite, nausea, stomach upset, irritability; generally considered to have fewer stimulant-like side effects like insomnia or appetite suppression, but can cause drowsiness and other GI effects; there is a pediatric safety warning about suicidality with antidepressant-like meds (discuss with clinician); monitor for mood changes.
- Important: always review individual risk factors (heart disease, severe anxiety, history of tics, bipolar disorder, suicidality, etc.) with a clinician.
- Dosing approach (general idea)
- Vyvanse: once-daily in the morning; dose is titrated up to a labeled maximum (often up to 70 mg/day for ADHD in many age groups; higher doses approved for some indications). Dosing is individualized.
- Qelbree: once-daily in the morning (dosing is individualized and titrated by the clinician; ranges exist depending on age and response). Start and adjust under medical supervision.
- Note: exact starting doses and maxes should come from the current prescribing information and your clinician.
- Which might be better for you (quick guidance)
- Choose Vyvanse if you want rapid symptom relief, have historically responded well to stimulants, or if adult ADHD and/or binge eating disorder treatment is a goal (when appropriate).
- Choose Qelbree if you want a non-stimulant option due to concerns about abuse potential, stimulant-related side effects (sleep disturbance, appetite suppression), or if there are tics, high anxiety, or substance-use concerns. Also consider if there’s a preference to avoid stimulant-type medications.
Practical tips
- If you’re switching medications, do so under your clinician’s guidance. Some people switch directly; others taper or use a cross-taper approach.
- If you have heart disease, high blood pressure, or mood concerns, discuss safety and monitoring with your clinician.
- Talk with your prescriber about comorbid conditions (anxiety, depression, tic disorders, sleep issues) and any other meds to anticipate interactions or additive side effects.
If you’d like, tell me:
- Age and any comorbid conditions (anxiety, tics, bipolar/depression, sleep problems)
- History of substance use or abuse risk
- Whether you’ve had good or poor responses to stimulants in the past
- Any specific concerns (sleep, appetite, mood, heart effects)
I can tailor the comparison to your situation and point you to the most relevant considerations or questions to ask your clinician.